Call 08047308287 81% Response Rate

Send Email

Anti Cancer Tablets

We are a leading Wholesaler of paleno palbociclib 125mg tablet, lynparza olaparib 150 mf tablets and bevacizumab injection from Ahmedabad, India.
Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet
  • Paleno Palbociclib 125mg Tablet

Paleno Palbociclib 125mg Tablet

Get Latest Price

Product Brochure

Product Details:
ManufacturerSun Pharma
Packaging Size1*21 Tablet Bottle
BrandPaleno
CompositionPalbociclib
Prescription/Non prescriptionPrescription
FormTablet
TreatmentHr+ve ,Her2_ve locally ABC or MBC

A) For Women:

 

Palbociclib Paleno is indicated for the treatment of HR+, HER2- locally ABC or mBC:

  • In combination with an AI
  • In combination with fulvestrant in women who have received prior ET

In premenopausal or perimenopausal women, ET should be combined with an LHRH agonist.

Get Best QuoteRequest A Callback
Lynparza Olaparib 150 MF Tablets
  • Lynparza Olaparib 150 MF Tablets
  • Lynparza Olaparib 150 MF Tablets
  • Lynparza Olaparib 150 MF Tablets
  • Lynparza Olaparib 150 MF Tablets
  • Lynparza Olaparib 150 MF Tablets

Lynparza Olaparib 150 MF Tablets

Get Latest Price

Product Brochure

Product Details:
Dose/Strength150mg 2 Tablet
Usage/ApplicationClinical
ManufacturerAstra Zaneca
BrandLynparza
Drug NameOlaparib 150 MG Tablet
Prescription/Non prescriptionPrescription
Packaging Size7*8 Tablet
FormTablet
TreatmentBRCA 1/2 Mutation position Breast cancer , Prostate Cancer , Adenocarcinoma of Pancreas

Breast cancer

Lynparza is indicated as:

• monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).

• monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

Adenocarcinoma of the pancreas

Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

Prostate cancer

Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.



Additional Information:

  • Packaging Details: Breast cancer Lynparza is indicated as: • monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). • monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. Adenocarcinoma of the pancreas Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. Prostate cancer Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Get Best QuoteRequest A Callback

Bevacizumab Injection

Product Price: Get Latest Price

Get Best QuoteRequest A Callback

EXPLORE MORE CATEGORIES

Contact Us
 
Thank youYour Enquiry has been sent successfully.
© Speciality Healthcare Solutions. All Rights Reserved (Terms of Use)Developed and managed by IndiaMART InterMESH Ltd.